This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Multiple myeloma
  • /
  • Clinical potential of SLAMF7 antibodies - focus on...

Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.

Read time: 1 mins
Published:20th Mar 2017
Author: Friend R, Bhutani M, Voorhees PM, Usmani SZ.
Availability: Free full text
Ref.:Drug Des Devel Ther. 2017;11:893-900.

Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and malignant plasma cells. This review summarizes the preclinical and clinical data that led to the approval of elotuzumab, along with a discussion on the ongoing and future clinical investigations.


Read abstract on library site

Access full article